Syros Pharmaceuticals (NASDAQ:SYRS) Upgraded to Hold by StockNews.com

StockNews.com upgraded shares of Syros Pharmaceuticals (NASDAQ:SYRSGet Rating) from a sell rating to a hold rating in a research report report published on Thursday.

Other equities analysts have also issued research reports about the stock. HC Wainwright reduced their price objective on shares of Syros Pharmaceuticals from $10.00 to $6.00 and set a buy rating for the company in a research report on Tuesday, July 12th. Alliance Global Partners reduced their price objective on shares of Syros Pharmaceuticals to $10.00 and set a buy rating for the company in a research report on Monday, May 16th. Finally, Oppenheimer reduced their price objective on shares of Syros Pharmaceuticals from $9.00 to $3.00 and set an outperform rating for the company in a research report on Wednesday, August 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus target price of $12.00.

Syros Pharmaceuticals Stock Performance

Shares of SYRS opened at $0.69 on Thursday. The firm has a 50-day moving average price of $0.87 and a 200 day moving average price of $0.96. The firm has a market capitalization of $43.50 million, a PE ratio of -0.40 and a beta of 1.62. The company has a quick ratio of 2.36, a current ratio of 2.36 and a debt-to-equity ratio of 1.10. Syros Pharmaceuticals has a 52-week low of $0.65 and a 52-week high of $5.48.

Syros Pharmaceuticals (NASDAQ:SYRSGet Rating) last announced its earnings results on Tuesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.12). The company had revenue of $6.28 million during the quarter, compared to the consensus estimate of $4.68 million. Syros Pharmaceuticals had a negative net margin of 433.67% and a negative return on equity of 157.22%. On average, sell-side analysts anticipate that Syros Pharmaceuticals will post -1.27 earnings per share for the current fiscal year.

Institutional Trading of Syros Pharmaceuticals

A number of hedge funds have recently bought and sold shares of SYRS. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Syros Pharmaceuticals by 14.8% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 118,632 shares of the company’s stock valued at $387,000 after buying an additional 15,325 shares in the last quarter. Ally Bridge Group NY LLC lifted its position in shares of Syros Pharmaceuticals by 2.9% in the fourth quarter. Ally Bridge Group NY LLC now owns 3,539,895 shares of the company’s stock worth $11,540,000 after purchasing an additional 100,000 shares in the last quarter. GSA Capital Partners LLP lifted its position in shares of Syros Pharmaceuticals by 119.4% in the fourth quarter. GSA Capital Partners LLP now owns 242,132 shares of the company’s stock worth $789,000 after purchasing an additional 131,795 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its position in shares of Syros Pharmaceuticals by 5.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,900,000 shares of the company’s stock worth $6,194,000 after purchasing an additional 100,000 shares in the last quarter. Finally, ACT Capital Management LLC lifted its position in shares of Syros Pharmaceuticals by 62.8% in the first quarter. ACT Capital Management LLC now owns 35,000 shares of the company’s stock worth $42,000 after purchasing an additional 13,500 shares in the last quarter. 84.19% of the stock is owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

(Get Rating)

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.

Featured Articles

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.